| Title |
Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies?
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, June 2015
|
| DOI | 10.1007/s00262-015-1720-6 |
| Pubmed ID | |
| Authors |
Beatriz Sanchez-Correa, Carmen Campos, Alejandra Pera, Juan M. Bergua, Maria Jose Arcos, Helena Bañas, Javier G. Casado, Sara Morgado, Esther Duran, Rafael Solana, Raquel Tarazona |
| Abstract |
Several age-associated changes in natural killer (NK) cell phenotype have been reported that contribute to the defective NK cell response observed in elderly patients. A remodelling of the NK cell compartment occurs in the elderly with a reduction in the output of immature CD56(bright) cells and an accumulation of highly differentiated CD56(dim) NK cells. Acute myeloid leukaemia (AML) is generally a disease of older adults. NK cells in AML patients show diminished expression of several activating receptors that contribute to impaired NK cell function and, in consequence, to AML blast escape from NK cell immunosurveillance. In AML patients, phenotypic changes in NK cells have been correlated with disease progression and survival. NK cell-based immunotherapy has emerged as a possibility for the treatment of AML patients. The understanding of age-associated alterations in NK cells is therefore necessary to define adequate therapeutic strategies in older AML patients. |
Mendeley readers
The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 2% |
| Unknown | 54 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 11 | 20% |
| Student > Ph. D. Student | 7 | 13% |
| Researcher | 6 | 11% |
| Student > Bachelor | 5 | 9% |
| Student > Doctoral Student | 5 | 9% |
| Other | 11 | 20% |
| Unknown | 10 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Immunology and Microbiology | 18 | 33% |
| Medicine and Dentistry | 10 | 18% |
| Agricultural and Biological Sciences | 8 | 15% |
| Biochemistry, Genetics and Molecular Biology | 7 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
| Other | 1 | 2% |
| Unknown | 10 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 January 2022.
All research outputs
#3,420,662
of 23,577,654 outputs
Outputs from Cancer Immunology, Immunotherapy
#235
of 2,948 outputs
Outputs of similar age
#45,250
of 267,938 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#4
of 40 outputs
Altmetric has tracked 23,577,654 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,948 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 267,938 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.